These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24523497)

  • 1. Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients.
    Srinivasa S; Grinspoon SK
    Eur J Endocrinol; 2014 May; 170(5):R185-202. PubMed ID: 24523497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
    Guaraldi G; Zona S; Orlando G; Carli F; Stentarelli C; Luzi K; Garlassi E; Menozzi M; Bagni P; Adorni F
    Clin Drug Investig; 2011 Nov; 31(11):759-67. PubMed ID: 21919542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors.
    Sension M; Deckx H
    AIDS Rev; 2015; 17(1):21-36. PubMed ID: 25472015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulations.
    Caron-Debarle M; Boccara F; Lagathu C; Antoine B; Cervera P; Bastard JP; Vigouroux C; Capeau J
    Curr Pharm Des; 2010 Oct; 16(30):3352-60. PubMed ID: 20687886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic effects of protease inhibitor therapy.
    Bernasconi E
    AIDS Read; 1999 Jul; 9(4):254-6, 259-60, 266-9. PubMed ID: 12737115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of inflammation to fat redistribution and metabolic disturbances in HIV-1 infected patients.
    Stankov MV; Behrens GM
    Curr Pharm Des; 2010 Oct; 16(30):3361-71. PubMed ID: 20687889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
    Blümer RM; van Vonderen MG; Sutinen J; Hassink E; Ackermans M; van Agtmael MA; Yki-Jarvinen H; Danner SA; Reiss P; Sauerwein HP
    AIDS; 2008 Jan; 22(2):227-36. PubMed ID: 18097225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients.
    Chen D; Misra A; Garg A
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4845-56. PubMed ID: 12414837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipotoxicity on the basis of metabolic syndrome and lipodystrophy in HIV-1-infected patients under antiretroviral treatment.
    Giralt M; Díaz-Delfín J; Gallego-Escuredo JM; Villarroya J; Domingo P; Villarroya F
    Curr Pharm Des; 2010 Oct; 16(30):3371-8. PubMed ID: 20687888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance in treated HIV infection.
    Feeney ER; Mallon PW
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):443-58. PubMed ID: 21663838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment.
    Lagathu C; Béréziat V; Gorwood J; Fellahi S; Bastard JP; Vigouroux C; Boccara F; Capeau J
    Expert Opin Drug Saf; 2019 Sep; 18(9):829-840. PubMed ID: 31304808
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients.
    Kim RJ; Rutstein RM
    Paediatr Drugs; 2010 Jun; 12(3):187-99. PubMed ID: 20481647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipokines levels in HIV infected patients: lipocalin-2 and fatty acid binding protein-4 as possible markers of HIV and antiretroviral therapy-related adipose tissue inflammation.
    Morieri ML; Guardigni V; Sanz JM; Dalla Nora E; Soavi C; Zuliani G; Sighinolfi L; Passaro A
    BMC Infect Dis; 2018 Jan; 18(1):10. PubMed ID: 29304747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipodystrophy syndrome: the morphologic and metabolic effects of antiretroviral therapy in HIV infection.
    Norris A; Dreher HM
    J Assoc Nurses AIDS Care; 2004; 15(6):46-64. PubMed ID: 15538016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence.
    Willig AL; Overton ET
    Curr HIV/AIDS Rep; 2016 Oct; 13(5):289-96. PubMed ID: 27541600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral therapy with heart.
    Randell P; Moyle G
    Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV and increased risk of cardiovascular diseases.
    Das S
    Sex Health; 2005; 2(4):219-21. PubMed ID: 16402668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.
    Grinspoon SK
    Am J Med; 2005 Apr; 118 Suppl 2():23S-28S. PubMed ID: 15903292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.